Assembly Biosciences (V7B) Stock Overview
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
V7B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Assembly Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.60 |
| 52 Week High | US$33.50 |
| 52 Week Low | US$6.98 |
| Beta | 1.17 |
| 1 Month Change | 29.37% |
| 3 Month Change | 49.54% |
| 1 Year Change | 113.07% |
| 3 Year Change | 110.68% |
| 5 Year Change | n/a |
| Change since IPO | -81.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| V7B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.2% | 0.7% | 1.6% |
| 1Y | 113.1% | -27.6% | 11.5% |
Return vs Industry: V7B exceeded the German Biotechs industry which returned -27.6% over the past year.
Return vs Market: V7B exceeded the German Market which returned 11.5% over the past year.
Price Volatility
| V7B volatility | |
|---|---|
| V7B Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: V7B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: V7B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 73 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses.
Assembly Biosciences, Inc. Fundamentals Summary
| V7B fundamental statistics | |
|---|---|
| Market cap | €510.61m |
| Earnings (TTM) | -€33.25m |
| Revenue (TTM) | €32.08m |
Is V7B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V7B income statement (TTM) | |
|---|---|
| Revenue | US$37.19m |
| Cost of Revenue | US$61.84m |
| Gross Profit | -US$24.65m |
| Other Expenses | US$13.90m |
| Earnings | -US$38.55m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | -66.28% |
| Net Profit Margin | -103.65% |
| Debt/Equity Ratio | 0% |
How did V7B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 22:05 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Assembly Biosciences, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Madhu Kumar | B. Riley Securities, Inc. |
| Irina Rivkind Koffler | Cantor Fitzgerald & Co. |